Biohaven Pharmaceutical Holding Co. Ltd. (BHVN)
Stock Price:
$71.20 USD
-1.19 (-1.64%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
4.17B |
| Revenue (ttm) |
1.15M |
| Net Income (ttm) |
-351.56M |
| Shares Out |
58.29M |
| EPS (ttm) |
-12.41 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 2, 2020 |
| Last Price |
$71.20 |
| Previous Close |
$72.39 |
| Change ($) |
-1.19 |
| Change (%) |
-1.64% |
| Day's Open |
72.99 |
| Day's Range |
69.92 - 73.11 |
| Day's Volume |
434,035 |
| 52-Week Range |
26.56 - 76.40 |
More Stats
| Market Cap |
4.17B |
| Enterprise Value |
3.74B |
| Earnings Date (est) |
Aug 18, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
58.29M |
| Float |
50.30M |
| EPS (basic) |
-7.89 |
| EPS (diluted) |
-12.41 |
| FCF / Share |
-8.99 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
10.31M |
| Short Ratio |
13.62 |
| Short % of Float |
24.25% |
| Beta |
1.41 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
3,620.76 |
| PB Ratio |
34.98 |
| Revenue |
1.15M |
| Operating Income |
-321.03M |
| Net Income |
-351.56M |
| Free Cash Flow |
-507.30M |
| Net Cash |
428.24M |
| Net Cash / Share |
7.32 |
| Gross Margin |
-25,126.15% |
| Operating Margin |
-27,891.66% |
| Profit Margin |
-30,543.40% |
| FCF Margin |
-44,074.37% |
| ROA |
-92.51% |
| ROE |
-584.04% |
| ROIC |
989.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (10)
| Buy |
9 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$84.20*
(18.26% upside)
Low
50.0
Current: 71.20
High
109.0
Target: 84.20
*Average 12-month price target from 10 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|
| Revenue | - | - | - | - | - |
| Operating Income | -225 | -108 | -108 | -60.64 | -9.70 |
| Net Income | -241 | -127 | -127 | -63.53 | -10.07 |
| Shares Outstanding | 39.19 | 27.85 | 27.85 | 12.61 | 11.01 |
| Earnings Per Share | -6.15 | -5.00 | -5.00 | -5.05 | -0.91 |
| Operating Cash Flow | -377 | -197 | -94.82 | -29.50 | -5.63 |
| Capital Expenditures | -3.78 | -4.17 | -0.54 | -0.03 | - |
| Free Cash Flow | -381 | -201 | -95.36 | -29.53 | -5.63 |
| Cash & Equivalents | 317 | 264 | 131 | 23.57 | 1.46 |
| Total Debt | - | - | - | 4.81 | - |
| Net Cash / Debt | 317 | 264 | 131 | 18.75 | 1.46 |
| Assets | 344 | 290 | 147 | 27.02 | 1.89 |
| Liabilities | 352 | 139 | 14.92 | 28.78 | 0.81 |
| Book Value | -7.42 | 151 | 132 | -45.03 | 1.14 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Biohaven Pharmaceutical Holding Co. Ltd. |
| Country |
United States |
| Employees |
647 |
| CEO |
Vlad Coric |
Stock Information
| Ticker Symbol |
BHVN |
| Stock Exchange |
New York Stock Exchange |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NYSE: BHVN |
| IPO Date |
May 4, 2017 |
Description
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases and rare disorders in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials for acute treatment and prevention of migraine; Vazegepant that has completed Phase 2/3 trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The company also offers Troriluzole that is in phase II/III clinical stage for obsessive compulsive disorders and Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trial for neuropsychiatric disorders; and Verdiperstat, a product that is in phase III trial for multiple system atrophy. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was founded in 2013 and is headquartered in New Haven, Connecticut.